Autism and its Medical Management / Michael G. CHEZ

Public ISBD Titre : Autism and its Medical Management : A Guide for Parents and Professionals Type de document : texte imprimé Auteurs : Michael G. CHEZ, Auteur Editeur : Londres [Angleterre] : Jessica Kingsley Publishers Année de publication : 2008 Importance : 224 p. Format : 17,6cm x 25,2cm x 1,2cm ISBN/ISSN/EAN : 978-1-84310-834-4 Note générale : Bibliogr., Index, Glossaire Langues : Anglais (eng) Mots-clés : Immunologie Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Résumé : Autism and its Medical Management explains the medical aspects of autism and how both parents and professionals can use current medical knowledge to better understand how to address the medical aspects of autism. The book begins with an overview of Autism Spectrum Disorders (ASDs) and how they are diagnosed, and goes on to identify the different types of autism and to describe relevant medical interventions. The author also provides an outline of recent research to enable parents and professionals to gain an understanding of the various factors that may contribute to the development of ASDs, as well as the latest available treatment options. Bridging the communication gap between medical professionals and parents, this book offers accessible explanations of medical terminology and treatment relevant to ASDs and is an important tool for parents and professionals working with children with ASDs. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491 Autism and its Medical Management : A Guide for Parents and Professionals [texte imprimé] / Michael G. CHEZ, Auteur . - Londres [Angleterre] : Jessica Kingsley Publishers, 2008 . - 224 p. ; 17,6cm x 25,2cm x 1,2cm. ISBN : 978-1-84310-834-4 Bibliogr., Index, Glossaire Langues : Anglais (eng) Mots-clés : Immunologie Index. décimale : AUT-B AUT-B - L'Autisme - Ouvrages généraux et scientifiques Résumé : Autism and its Medical Management explains the medical aspects of autism and how both parents and professionals can use current medical knowledge to better understand how to address the medical aspects of autism. The book begins with an overview of Autism Spectrum Disorders (ASDs) and how they are diagnosed, and goes on to identify the different types of autism and to describe relevant medical interventions. The author also provides an outline of recent research to enable parents and professionals to gain an understanding of the various factors that may contribute to the development of ASDs, as well as the latest available treatment options. Bridging the communication gap between medical professionals and parents, this book offers accessible explanations of medical terminology and treatment relevant to ASDs and is an important tool for parents and professionals working with children with ASDs. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=491

Exemplaires(1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
DOC0000538	AUT-B CHE	Livre	Centre d'Information et de Documentation du CRA Rhône-Alpes	AUT - Trouble du Spectre de l'Autisme (TSA)	Disponible

A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism / Michael G. CHEZ in Journal of Autism and Developmental Disorders, 50-5 (May 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-5 (May 2020) . - p.1532-1538 Titre : A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism Type de document : texte imprimé Auteurs : Michael G. CHEZ, Auteur ; Shawn KILE, Auteur ; Christopher LEPAGE, Auteur ; Carol PARISE, Auteur ; Bobbie BENABIDES, Auteur ; Andrea HANKINS, Auteur Article en page(s) : p.1532-1538 Langues : Anglais (eng) Mots-clés : Adults  Aggression  Autism spectrum disorder  Dextromethorphan  Irritability  Placebo controlled crossover trial  Quinidine Index. décimale : PER Périodiques Résumé : Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism. En ligne : http://dx.doi.org/10.1007/s10803-018-3703-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422 [article] A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism [texte imprimé] / Michael G. CHEZ, Auteur ; Shawn KILE, Auteur ; Christopher LEPAGE, Auteur ; Carol PARISE, Auteur ; Bobbie BENABIDES, Auteur ; Andrea HANKINS, Auteur . - p.1532-1538. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-5 (May 2020) . - p.1532-1538 Mots-clés : Adults  Aggression  Autism spectrum disorder  Dextromethorphan  Irritability  Placebo controlled crossover trial  Quinidine Index. décimale : PER Périodiques Résumé : Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism. En ligne : http://dx.doi.org/10.1007/s10803-018-3703-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422

Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism / Michael G. CHEZ in Autism Research and Treatment, (July 2012)  

Public ISBD [article]  inAutism Research and Treatment > (July 2012) . - 7 p. Titre : Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism Type de document : texte imprimé Auteurs : Michael G. CHEZ, Auteur ; Renee LOW, Auteur ; Carol PARISE, Auteur ; Tammy DONNEL, Auteur Année de publication : 2012 Article en page(s) : 7 p. Langues : Anglais (eng) Mots-clés : Lenalidomide Index. décimale : PER Périodiques Résumé : Autism affects 1 : 88 children in the United States. Familial history of autoimmune disease, autoantibodies in the serum of mothers when there is more than one autistic offspring, and neuroglial response in CSF and brain tissue in autistic patients suggest an immunological variable may be associated with this condition. Lenalidomide has the potential to invoke changes in TNF-α with less toxicity than thalidomide. This pilot study evaluated lenalidomide at reduction of TNF-α and improvement of behavior and language in children with autism with elevated TNF-α. Subjects with elevated TNF-α were given 2.5 mgs lenalidomide daily for 12-weeks. Pharmacodynamics and safety was evaluated. Changes in language and autistic behaviors after six and twelve weeks were measured. Although statistical significance was not achieved for most measures, there were trends toward improvement. After 6-weeks, mean receptive language increased: 60.67 ± 12.06 to 65.00 ± 15.10 (P = 0.11) and symptoms of autism decreased (40.75 ± 5.96 versus 38.67 ± 7.90, P = 0.068). After 12-weeks, CSF-TNF-α declined 57% ± 25% from 80.5 ± 41.03 to 38.0 ± 31.27 (P = 0.068). Serum TNF-α declined 57% (92.50 ± 68.92 to 40.25 ± 44.53 (P = 0.048). This study suggests that lenalidomide is tolerated as a treatment by children with autism and should be further studied as a potential agent for cytockine inflammation. En ligne : http://dx.doi.org/10.1155/2012/291601 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181 [article] Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism [texte imprimé] / Michael G. CHEZ, Auteur ; Renee LOW, Auteur ; Carol PARISE, Auteur ; Tammy DONNEL, Auteur . - 2012 . - 7 p. Langues : Anglais (eng) in Autism Research and Treatment > (July 2012) . - 7 p. Mots-clés : Lenalidomide Index. décimale : PER Périodiques Résumé : Autism affects 1 : 88 children in the United States. Familial history of autoimmune disease, autoantibodies in the serum of mothers when there is more than one autistic offspring, and neuroglial response in CSF and brain tissue in autistic patients suggest an immunological variable may be associated with this condition. Lenalidomide has the potential to invoke changes in TNF-α with less toxicity than thalidomide. This pilot study evaluated lenalidomide at reduction of TNF-α and improvement of behavior and language in children with autism with elevated TNF-α. Subjects with elevated TNF-α were given 2.5 mgs lenalidomide daily for 12-weeks. Pharmacodynamics and safety was evaluated. Changes in language and autistic behaviors after six and twelve weeks were measured. Although statistical significance was not achieved for most measures, there were trends toward improvement. After 6-weeks, mean receptive language increased: 60.67 ± 12.06 to 65.00 ± 15.10 (P = 0.11) and symptoms of autism decreased (40.75 ± 5.96 versus 38.67 ± 7.90, P = 0.068). After 12-weeks, CSF-TNF-α declined 57% ± 25% from 80.5 ± 41.03 to 38.0 ± 31.27 (P = 0.068). Serum TNF-α declined 57% (92.50 ± 68.92 to 40.25 ± 44.53 (P = 0.048). This study suggests that lenalidomide is tolerated as a treatment by children with autism and should be further studied as a potential agent for cytockine inflammation. En ligne : http://dx.doi.org/10.1155/2012/291601 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181

---

1 (1 - 3 / 3) Par page : 25 50 100 200